chloramphenicol stearate: structure in Negwer, 5th ed, #5784 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 83945 |
| CHEBI ID | 177426 |
| SCHEMBL ID | 10791882 |
| MeSH ID | M0100175 |
| Synonym |
|---|
| CHEBI:177426 |
| [(2r,3r)-2-[(2,2-dichloroacetyl)amino]-3-hydroxy-3-(4-nitrophenyl)propyl] octadecanoate |
| D07674 |
| 16255-48-4 |
| quemicetina (tn) |
| chloroamphenicol stearate |
| (r-(r*,r*))-2-((dichloroacetyl)amino)-3-hydroxy-3-(4-nitrophenyl)propyl stearate |
| stearic acid, ester with chloramphenicol |
| levomycetin stearate |
| 2,2-dichloro-n-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)acetamide alpha-stearate |
| stearic acid, alpha-ester with d-threo-(-)-2,2-dichloro-n-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)acetamide |
| chloramphenicol monostearate |
| madomicetina |
| brn 2797487 |
| octadecanoic acid, (2r,3r)-2-((dichloroacetyl)amino)-3-hydrdoxy-3-(4-nitrophenyl)propyl ester |
| chloroamphenicol stearic acid ester |
| octadecanoic acid, 2-((dichloroacetyl)amino)-3-hydroxy-3-(4-nitrophenyl)propyl ester, (r-(r*,r*))- |
| eusynthomycin |
| chloramphenicol stearate |
| einecs 240-363-4 |
| AKOS005267198 |
| 4-13-00-02754 (beilstein handbook reference) |
| dl2a9m9d6x , |
| unii-dl2a9m9d6x |
| (-)-chloramphenicol stearate |
| chloramphenicol stearic acid ester |
| chloramphenicol stearate [who-dd] |
| octadecanoic acid, (2r,3r)-2-((2,2-dichloroacetyl)amino)-3-hydroxy-3-(4-nitrophenyl)propyl ester |
| SCHEMBL10791882 |
| DTXSID20167407 |
| (2r,3r)-2-[(dichloroacetyl)amino]-3-hydroxy-3-(4-nitrophenyl)propyl stearate |
| Q27276455 |
| (2r,3r)-2-(2,2-dichloroacetamido)-3-hydroxy-3-(4-nitrophenyl)propyl stearate |
| AKOS040746696 |
| Class | Description |
|---|---|
| C-nitro compound | A nitro compound having the nitro group (-NO2) attached to a carbon atom. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.44) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||